Search PubMed⌕ Search

Biomedical subjects

H H Gunson

Publications and source records attributed to H H Gunson.

At least 19 recordsLinked to original sources

Pilot trials of PDF symbology as a means of transfering data on blood units between transfusion centres.

PDF 417, a two-dimensional barcode, was used as a portable data file to transfer key information on blood units and delivery documentation between two Regional Blood Transfusion Centres. Multiple Codabar messages currently displayed on blood packs, as well as other useful information, i.e. microbiology conformance, were encoded in a 45-character single PDF barcode. The delivery note which accompanied each consignment of blood consisted of a series of PDF barcodes, each representing 20 blood units. Computer validation showed 100% reconciliation of PDF data with Codabar data. Readability of the code was excellent with a greater than 98% first-pass read rate. The delivery note PDF barcode identified eight operator errors which would have been undetected by the present manual system. We conclude that PDF 417 is an effective, secure and space efficient means of transferring data associated with the transfer of blood.

Blood Banks↗

U.K. multicentre study on blood donors for surrogate markers of non-A non-B hepatitis. Part I: Alanine transferase and anti-HBc testing.

Blood samples from 9,215 blood donors in three U.K. centres (North London, Bristol and Manchester) were tested for their alanine aminotransferase (ALT) level and the presence of anti-HBc and anti-HCV. This paper presents the results of the ALT and anti-HBc tests. The prevalence of ALT > 45 IU/l was 3.1% overall (North London 3.06%, Bristol 4.56% and Manchester 1.97%). Manchester results were skewed by the methodology used for ALT measurement, highlighting the need for standard test methods. Anti-HBc was detected using the Wellcome enzyme-immunosorbent assay (EIA) and confirmatory testing was performed using a radioimmunoassay (RIA) and the Corecell haemagglutination assay. Repeat reactive rates were 0.9, 0.79 and 0.94% for North London, Bristol and Manchester, respectively, with an overall rate of 0.9%. The confirmed positive rate was 0.73, 0.53 and 0.65% for the three centres with an overall rate of 0.63%. Donors with an ALT > 45 IU/l, or with confirmed anti-HBc, were interviewed with a medical questionnaire for risk factors. The major contributing factors in donors with a raised ALT were alcohol consumption and obesity.

Adolescent↗

Screening of blood donations for HIV-1 antibody: 1985-1991.

One hundred and ninety HIV-1 antibody positive donors have been detected, out of 14.85 million blood donations screened in the United Kingdom and the Isle of Man, since the start of testing in October 1985 to the end of March 1991. There were 145 men and 45 women, with an overall seropositivity rate of 0.001%. Records for new donors (ie, those donating for the first time) have been kept since February 1986 and 79 out of 1.9 million donations have been seropositive (58 men and 21 women); a rate of 0.004%. One hundred and forty-one (74.2%) of the 190 positive donors were found to have been exposed to a high risk of HIV infection. Twenty-four (13%) denied any exposure other than heterosexual intercourse with partners who were not considered to be at high risk. In six cases the partners were from countries where the main route of transmission is heterosexual. Seven donors (4%) attributed infection to some other cause. Eighteen (9.5%) have been lost to follow-up, are still being investigated or have not yet been interviewed. Combined tests which screen for both HIV-1 and HIV-2 antibodies were introduced in June 1990. The last 2.55 million donations (including 370,000 new donors) have been tested with these kits. One HIV-2 antibody positive donation had been confirmed in a new donor by the end of March 1991.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗

Comparison of false-positive reactions in direct-binding anti-HIV ELISA using cell lysate or recombinant antigens.

In a 2-year study of false-positive anti-HIV-1 tests in blood donors at Manchester and Lancaster Blood Banks, the reactions associated with a HIV-infected cell lysate antigen were compared with those using recombinant-antigen-based tests. In year 1 (cell lysate test) at Manchester BTS 0.21% of 119.178 donations were repeatedly reactive, compared with 0.53% of 119,004 donations in year 2 (recombinant antigen). Reactive sera were tested at Manchester PHL by three different immunoassays. Referred specimens were classified as anti-HIV positive (95-100% reactive in all the assays), equivocal or negative (negative results in all three immunoassays). Two donors were confirmed to be anti-HIV positive over the 2-year period. Most sera were negative by confirmatory immunoassays in years 1 and 2. In year 1, a study of 60 referred sera with sex- and age-matched controls showed high correlation between a reactive anti-HIV-1 screening test and indeterminate anti-HIV-1 patterns on Western blot showing reactions with HIV gag-coded proteins. In year 2, less than 10% of referred sera were reactive by Western blot, and there was no correlation between a reactive screening anti-HIV test, the strength of signal in the test or a reactive Western blot. Follow-up showed that donors whose sera were reactive in years 1 and 2 by the anti-HIV-1 screening test formed almost two different populations. Four donors with equivocal anti-HIV-1 confirmatory tests had anti-HIV 'envelope' reactions.(ABSTRACT TRUNCATED AT 250 WORDS)

Blotting, Western↗

AIDS update.

Explore the source record for details and available documents.

Acquired Immunodeficiency Syndrome↗

HIV antibody screening of blood donations in the United Kingdom.

Routine screening of blood donations for anti-HIV commenced in the UK during October 1985 and by the end of February 1987 approximately 3.7 million donations had been tested. Seventy-two were confirmed anti-HIV positive, i.e. 0.002%. Of the anti-HIV-positive donors interviewed to date, the majority are young homosexual or bisexual men or intravenous drug abusers. Included in the study are data collected on approximately 470,000 donors giving blood for the first time. Twenty of these have been confirmed anti-HIV positive (0.004%), and 19 interviewed have admitted to being in risk categories. In 5 instances a positive anti-HIV donor was found negative on a previous occasion, and in 1 instance the products from the donation led to seroconversion in the recipients. The majority of anti-HIV-positive donors attending for blood donation did so because they did not consider that the self-exclusion categories specified in the leaflet issued to donors applied to them since homosexual activity or drug abuse was not currently being practised.

Acquired Immunodeficiency Syndrome↗

Detection of carotenoids in blood donors taking Orobronze: a cautionary note.

During the summer, plasma samples from eight blood donors at this transfusion centre were found to have a bright orange colour. All donors appeared to be healthy and haematological tests showed no abnormality. Extracts of lipid from the plasma revealed the presence of the carotenoid canthaxanthin and other carotenoid metabolites which were identified by thin-layer chromatography and high-pressure liquid chromatography, light absorbtion and mass spectrometry. On questioning the donors it was found that they had been taking a course of 'Orobronze' (an oral 'bronzing' treatment containing canthaxanthin). Canthaxanthin was still detectable in the plasma several months after the donors had ceased taking the capsules. At present it seems that there would be no deleterious effects on healthy individuals taking orobronze. The full implications of the presence of canthaxanthin in plasma transfused to patients do, however, require further investigation of carotenoid metabolism in man.

Blood Donors↗

Five-day storage of platelet concentrates. I. In-vitro studies.

Platelet concentrates have been prepared in standard PVC (PL-146) packs and polyolefin (PL-732) packs. Comparison of pH and hypotonic stress of the platelet concentrates has shown that significantly improved values are obtained after storage of the concentrates at 22 C in PL-732 packs for 5 days than after storage for 3 days in PL-146 packs. There was no significant difference under conditions of the test between vertical and horizontal agitation of the concentrates. Since both pH and hypotonic stress recovery have shown a relationship to post-transfusion recovery and viability, evidence is presented to support the 5-day storage period of concentrates prepared and stored in PL-732 packs.

Blood Platelets↗

Five-day storage of platelet concentrates. II. In-vivo studies.

Following in-vitro tests it was concluded that platelet concentrates stored for 5 days at 22 degrees C in polyolefin containers, coded PL732, should be as effective in clinical practice as similar concentrates stored in the standard PVC containers, coded PL146. These predictions have been confirmed by the following in-vivo tests; autologous survival studies in volunteers, determination of recovery, platelet increment calculations 1 and 24 h after transfusion and clinical appraisal after transfusion of haemorrhagic thrombocytopenic patients. Bacteriological cultures of the platelet concentrates were sterile after storage for more than 5 days. It can be concluded that the 5-day storage of platelet concentrates in these containers is a practical proposition.

Blood↗

Maternal anti-D concentrations and outcome in rhesus haemolytic disease of the newborn.

The relation between maternal anti-D concentrations, measured against the British working standard, and outcome of rhesus-sensitised pregnancies was studied. There is a clear relation between increasing anti-D concentrations and the chance of a severely affected baby. Of those pregnancies (78) where serial anti-D concentrations remained below 4 IU/ml, no baby had a cord haemoglobin below 10 g/dl and three had exchange transfusions. In contrast, of those mothers (106) with anti-D concentrations above 4 IU/ml, 23 had babies with a cord haemoglobin below 10 g/dl and 79 babies had exchange transfusions. It is suggested that those pregnancies where anti-D concentrations remain below 4 IU/ml represent a relatively safe group in which amniocentesis may be avoided.

Bilirubin↗